Overview

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to study how the elderly patients who have previously undergone treatment for acute myeloid leukemia and high-rRisk myelodysplastic syndromes, respond to a combined treatment with azacitidine and lenalidomide.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
Celgene Corporation
Treatments:
Azacitidine
Lenalidomide
Thalidomide